The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The harmful health effects of recreational ecstasy: a systematic review of observational evidence
Open accessAbstract
Objectives To investigate the harmful health effects of taking ecstasy (3,4-methylenedioxymethamphetamine, MDMA) for recreational purposes. Data sources MEDLINE, EMBASE, PsycINFO and Web of Knowledge were searched. Additional information on deaths was collected from the General Mortality Register (GMR) and the Special Mortality Register collated by the National Programme on Substance Abuse Deaths (np-SAD). Review methods Studies were categorised according to design, with systematic research syntheses (Level I evidence) the most valid and least open to bias. Where Level I evidence was not available, controlled observational studies (Level II evidence) were systematically reviewed. If neither Level I nor Level II evidence was available, uncontrolled case series and case reports (Level III evidence) were systematically surveyed. Data were extracted by one reviewer and a sample checked by a second. The heterogeneity of Level II evidence was addressed by undertaking stratified analyses for current and former ecstasy users and comparing them either with control groups using other illegal drugs but not ecstasy (polydrug controls) or with controls naïve to illegal drugs (drug-naïve controls). Statistical heterogeneity was minimised by using a random-effects model throughout and investigated using study-level regression analysis (metaregression). Results Five Level I syntheses were identified; for each it was difficult to ascertain the exact methods adopted and evidence included. Small but significant deficits for ecstasy users compared to controls were reported in areas relating to attention, memory, psychomotor speed, executive systems functioning, and self-reported depressive symptoms. Data from Level II studies were directly pooled for seven individual outcomes, suggesting that ecstasy users performed worse than controls on common measures of immediate and delayed verbal recall (RAVLT, RBMT, digit span). No difference was seen in IQ (NART). The 915 outcome measures identified in Level II studies were analysed in broad domains: immediate and delayed verbal and visual memory, working memory, two measures of attention, three measures of executive function, perceptual organisation, self-rated depression, memory and anxiety, and impulsivity measured objectively and subjectively. Ecstasy users performed significantly worse than polydrug controls in 13/16 domains and significantly worse than drug-naïve controls in 7/12 domains for which sufficient data were available. The largest, most consistent exposure effects were seen in meta-analyses of memory (especially verbal and working memory, with less marked effects seen in visual memory). Former ecstasy users frequently showed deficits that matched or exceeded those seen amongst current users. At aggregate level, the effects do not appear to be dose-related, but are variably confounded by other drug use, particularly alcohol. Of Level III evidence, in the 10 years to 2006, the np-SAD and the GMR recorded an average of around 50 drug-related deaths per year involving ecstasy; it was the sole drug implicated in around 10 cases per year. Retrospective case series, based on hospital emergency department records, reported a death rate of 0–2% from emergency admissions related to ecstasy. Two major syndromes are most commonly reported as the immediate cause of death in fatal cases: hyperthermia and hyponatraemia. Conclusions A broad range of relatively low-quality literature suggests that recreational use of ecstasy is associated with significant deficits in neurocognitive function (particularly immediate and delayed verbal memory) and increased psychopathological symptoms. The clinical significance of the exposure effect in individual cases will be variable but, on average, deficits are likely to be relatively small. Ecstasy is associated with a range of acute harms but appears to be a rare cause of death in isolation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of the elements of attention: A neuropsychological approach
Mirsky, A. F., Anthony, B. J., Duncan, C. C., Ahearn, M. B., & Kellam, S. G. (1991) · Neuropsychology Review · doi:10.1007/bf01109051 · Cited by 874
Subjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413
Cited by
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
Organ Preservation: Current Concepts and New Strategies for the Next Decade
Guibert, E. E., Petrenko, A. Y., Balaban, C. L., Somov, A. Y., Rodriguez, J. V., & Fuller, B. J. (2011) · Transfusion Medicine and Hemotherapy · doi:10.1159/000327033 · Cited by 354
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Lewer, D., Freer, J., King, E., Larney, S., Degenhardt, L., Tweed, E. J., Hope, V. D., Harris, M., Millar, T., Hayward, A., et al. (2020) · Addiction · doi:10.1111/add.14892 · Cited by 161
Sessa, B. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.004 · Cited by 97
Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders
Harada, T., Tsutomi, H., Mori, R., & Wilson, D. B. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011315.pub2 · Cited by 76
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
MDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Kamboj, S. K., Kilford, E. J., Minchin, S., Moss, A., Lawn, W., Das, R. K., Falconer, C. J., Gilbert, P., Curran, H. V., & Freeman, T. P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115587143 · Cited by 43
Steenbock, B., Pischke, C. R., Schönbach, J., Pöttgen, S., & Brand, T. (2015) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-014-2100-7 · Cited by 17
Metadata
- Authors
- Rogers, G., Elston, J., Garside, R., Roome, C., Taylor, R., Younger, P., Zawada, A., & Somerville, M.
- Venue
- Health Technology Assessment
- Published
- 2009-02
- Volume
- 13
- Issue
- 6
- Pages
- 1-354
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W4231441734
- Cited by
- 266
- References
- 2
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.